Shaolei Lu

Brown University Warren Alpert Medical School
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45 mg and one patient received 30 mg. The time to the maximum concentration of copanlisib when administered in combination with rucaparib ranged between 0.5 and 4 hours. The mean terminal half-life was 41.4 ± 56.7 hours. The mean clearance was 32,656 ± 18,164 mL/hour. These parameters are consistent with historical PK parameters of copanlisib.

Year:

2025

Purpose: Metastatic castration-resistant prostate cancer with homologous recombination (HR) deficiency (HRD) is sensitive to PARP inhibitors (PARPi). PI3K inhibitors (PI3Ki) sensitize to PARPi by disrupting HR in preclinical models. This phase Ib/II study investigated copanlisib (Copa; pan–class I PI3Ki) and rucaparib (R). Patients and Methods: Eligible patients had metastatic castration-resistant prostate cancer treated with ≥1 androgen receptor inhibitor and taxanes. Phase I followed a standard 3 + 3 dose-escalation design (rucaparib 400–600 mg orally twice a day; Copa 45–60 mg i.v. on days 1, 8, and 15). Primary goal of phase I was to establish MTD and the recommended phase II dose. The primary endpoint of phase II was PSA50 response rate. Results: Thirteen patients enrolled had a median age of 64 (55–78) years and PSA was 11.7 ng/mL (0.018–2,101). Seven patients received taxanes, and one patient received PARPi. Eight patients had HRD+ tumors [ BRCA2 (four), BRCA1 (one), RAD51C (one), CDK12 (one), and FANCA (one)] and three had PTEN loss. There were two dose-limiting toxicities in dose level 1 (rucaparib 400 mg twice a day; Copa 45 mg on days 1, 8, and 15): grade 3 rash and aspartate aminotransferase/alanine aminotransferase elevation. Treatment-related adverse events ≥ grade 2 included leukopenia (54%), anemia (38%), rash (30%), fatigue (23%), and neutropenia (23%). Six patients were treated at dose level –1 without dose-limiting toxicities, which was established as the recommended phase II dose (rucaparib 400 mg twice a day + Copa 45 mg on day 1/15). Among patients with HRD+, one had confirmed partial response and three had stable disease by RECIST, including one patient treated with prior PARPi, and three patients had PSA50 responses (23%). Conclusions: Copa/R had an acceptable safety profile with a signal of efficacy supporting future studies of PARPi with PI3Ki. Significance: Gene alterations in the PI3K and HR pathways are common in prostate cancer. Based on preclinical studies, the inhibition of PI3K disrupts HR, and PARP blockade induces AKT activation, supporting the combination of PI3Ki and PARPi. Herein, we investigated the safety and preliminary efficacy of the PI3Ki copanlisib and the PARPi rucaparib in patients with or without alterations in HR repair pathway genes.

Year:

2025

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Benedito A. Carneiro

-

UNITED STATES
View details

Sheldon Holder

Assistant Professor

Brown University

UNITED STATES
View details

Adam Olszewski

Associate Professor of Medicine

Rhode Island Hospital

UNITED STATES
View details

Wafik S. El-Deiry

Associate Dean, Oncologic Sciences

Brown University

UNITED STATES
View details

Rahul Aggarwal

University of California

UNITED STATES
View details